SFDA To Segregate Responsibilities Of Drug Administration, Appraisal And Approval
This article was originally published in PharmAsia News
Executive Summary
According to its recently published reorganization plan, China's State FDA will spread the control of drug administration, appraisal and approval into different bureaus. For instance, a new food permission bureau will be set up to exclusively approve food, cosmetics and healthcare products, while other bureaus will manage related responsibilities. In addition, SFDA will transfer the jurisdiction of technology appraisal on drug and medical devices to its lower level institutions, the National Institute for the Control of Pharmaceutical and Biological Products, Chinese Pharmacopoeia Commission, Center for Drug Evaluation and Medical Devices Evaluation Center. SFDA will now approve and supervise healthcare products. The constant policy revision means imminent change in the industry's product brand names, R&D and classification. (Click here for more - Chinese Language)